Andrea Buono
A5018004237- Cardiac Valve Diseases and Treatments
- Infective Endocarditis Diagnosis and Management
- Coronary Interventions and Diagnostics
- Aortic Disease and Treatment Approaches
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Cardiovascular Function and Risk Factors
- Cerebrovascular and Carotid Artery Diseases
- COVID-19 and healthcare impacts
- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Heart Failure Treatment and Management
- Kawasaki Disease and Coronary Complications
- Cardiac Structural Anomalies and Repair
- Aortic aneurysm repair treatments
- Eosinophilic Disorders and Syndromes
- Healthcare cost, quality, practices
- Peripheral Artery Disease Management
- Coronary Artery Anomalies
- Antiplatelet Therapy and Cardiovascular Diseases
- Histiocytic Disorders and Treatments
- Vascular Procedures and Complications
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Heart rate and cardiovascular health
- Infectious Aortic and Vascular Conditions
Fondazione Poliambulanza Istituto Ospedaliero
2021-2025
Istituto Clinico Sant'Ambrogio
2020-2023
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2018-2023
Montefiore Medical Center
2023
Albert Einstein College of Medicine
2023
Society of Interventional Radiology
2021
Johannes Gutenberg University Mainz
2019-2020
Charles University
2020
University Hospital Kralovske Vinohrady
2020
University of Milano-Bicocca
2018-2019
The ACURATE neo2 (NEO2) and Evolut PRO/PRO+ (PRO) bioprostheses are new-generation self-expanding valves developed for transcatheter aortic valve replacement (TAVR).
Treatment of aortic stenosis in patients with small annuli is challenging and can result prosthesis-patient mismatch (PPM).
There is a lack of evidence to guide treatment patients with concomitant indication for transcatheter aortic valve implantation (TAVI) and complex, high-risk percutaneous coronary intervention (PCI). We aimed assess different strategies PCI timing in this TAVI cohort. The ASCoP registry retrospectively included clinical both at least 1 criterion complex or PCI. primary endpoint was composite all-cause death unplanned rehospitalisation cardiovascular causes. secondary death, stroke, acute...
Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim this study was to investigate temporal trends assess contemporary after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This included patients enrolled multicenter NEOPRO (A Multicenter Comparison Acurate NEO Versus PRO...
Transcatheter aortic valve replacement (TAVR) in patients with bicuspid (BAV) stenosis is technically challenging and burdened by an increased risk of paravalvular regurgitation (PVR).
Transcatheter aortic valve replacement (TAVR) with the ACURATE neo device has been associated a non-negligible incidence of paravalvular regurgitation (AR). The new-generation neo2 designed to mitigate this limitation.The aim study was compare TAVR and devices.The NEOPRO NEOPRO-2 registries retrospectively included patients undergoing transfemoral self-expanding valves at 24 20 centres, respectively. Patients receiving devices (from January 2012 December 2021) were in study. Predischarge...
Transcatheter aortic valve replacement (TAVR) is an effective treatment option for patients with severe, symptomatic AS, regardless of the transcatheter heart (THV) implanted. Prior studies demonstrated a higher device success lower paravalvular leak (PVL) using balloon-expandable (BE) Sapien/XT THV vs. self-expanding (SE) THV. However, few data are available on performance novel BE
De novo diffuse coronary artery disease (CAD) is a challenging scenario in interventional cardiology with limited treatment option, beside stent implantation. In this context, hybrid approach, combining the use of drug-eluting (DES) and drug-coated balloon (DCB) to treat different segments same lesion (e.g. long and/or true bifurcation), might be an interesting alternative strategy limit metal amount. The aim study was evaluate safety efficacy approach addressing percutaneous de CAD.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) is an established management strategy for severe stenosis. Percutaneous axillary approach TAVI holds the promise of improving safety without jeopardizing effectiveness in comparison to surgical access. We aimed at appraising comparative percutaneous vs. approaches TAVI.METHODS: performed international retrospective observational study using de-identified details on baseline, procedural, and 1-month follow-up features. Valve Academic...
Aims: The aim of this study was to compare five-year clinical outcomes between an everolimus-eluting bioresorbable scaffold (BRS) and metallic stent (EES) in STEMI patients. Methods results: This observational retrospective included 235 consecutive patients treated with BRS, compared EES from the EXAMINATION trial, by applying propensity score matching. primary endpoint a device-oriented (DOCE), including cardiac death, target vessel myocardial infarction lesion revascularisation at...
We evaluate feasibility and reproducibility of post hoc quantitative flow ratio (QFR) measurements their prognostic predictive power during long-term follow-up. Between 2010 2012, 167 patients without angiographic evidence significant stenoses were enrolled in a prospective registry. Of these patients, 96% presented 7 years follow-up data. QFR was measured by three certified investigators. analysis feasible 71% left anterior descending (LAD), 72% circumflex (LCX), 61% right (RCA) coronaries...
Abstract Objectives To explore the long‐term clinical outcomes following intravascular lithotripsy (IVL) in calcified coronary lesions from a real‐world population. Background IVL is relatively new but promising modality for treating lesions, there dearth of outcome data patients. Methods This was multicenter, observational study which we enrolled all patients treated with November 2018 to February 2021 eight centers Europe and United Kingdom. Procedural success, complications, (cardiac...
Background The impact of complete revascularization (CR) on the development heart failure (HF) in patients with acute coronary syndrome and multivessel artery disease undergoing percutaneous intervention remains to be elucidated. Methods Results Consecutive from CORALYS (Incidence Predictors Heart Failure After Acute Coronary Syndrome) registry were included. Incidence first hospitalization for HF or cardiovascular death was primary end point. Patients stratified according completeness...